1. Home
  2. GNPX vs SONM Comparison

GNPX vs SONM Comparison

Compare GNPX & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • SONM
  • Stock Information
  • Founded
  • GNPX 2009
  • SONM 1999
  • Country
  • GNPX United States
  • SONM United States
  • Employees
  • GNPX N/A
  • SONM N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • SONM Telecommunications Equipment
  • Sector
  • GNPX Health Care
  • SONM Telecommunications
  • Exchange
  • GNPX Nasdaq
  • SONM Nasdaq
  • Market Cap
  • GNPX 10.8M
  • SONM 12.1M
  • IPO Year
  • GNPX 2018
  • SONM 2019
  • Fundamental
  • Price
  • GNPX $6.64
  • SONM $11.22
  • Analyst Decision
  • GNPX
  • SONM
  • Analyst Count
  • GNPX 0
  • SONM 0
  • Target Price
  • GNPX N/A
  • SONM N/A
  • AVG Volume (30 Days)
  • GNPX 1.7M
  • SONM 58.6K
  • Earning Date
  • GNPX 11-14-2025
  • SONM 11-12-2025
  • Dividend Yield
  • GNPX N/A
  • SONM N/A
  • EPS Growth
  • GNPX N/A
  • SONM N/A
  • EPS
  • GNPX N/A
  • SONM N/A
  • Revenue
  • GNPX N/A
  • SONM $57,917,000.00
  • Revenue This Year
  • GNPX N/A
  • SONM $127.68
  • Revenue Next Year
  • GNPX N/A
  • SONM N/A
  • P/E Ratio
  • GNPX N/A
  • SONM N/A
  • Revenue Growth
  • GNPX N/A
  • SONM N/A
  • 52 Week Low
  • GNPX $6.51
  • SONM $9.38
  • 52 Week High
  • GNPX $140.00
  • SONM $114.84
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 63.07
  • SONM 96.04
  • Support Level
  • GNPX $7.71
  • SONM $0.66
  • Resistance Level
  • GNPX $9.89
  • SONM $12.30
  • Average True Range (ATR)
  • GNPX 1.15
  • SONM 0.31
  • MACD
  • GNPX 0.53
  • SONM 1.24
  • Stochastic Oscillator
  • GNPX 50.54
  • SONM 90.71

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: